TARKA 180 MG
VERAPAMIL HYDROCHLORIDE : 180 MG TRANDOLAPRIL : 2 MG · DIN 02238096 · ABBOTT LABORATORIES, LIMITED
Health Canada status: CANCELLED POST MARKET
What is TARKA?
TARKA 180 MG contains VERAPAMIL HYDROCHLORIDE : 180 MG TRANDOLAPRIL : 2 MG. It is listed in the Health Canada Drug Product Database under DIN 02238096, held by ABBOTT LABORATORIES, LIMITED, supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 12-Nov-2010. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TARKA used for?
TARKA (trandolapril/verapamil hydrochloride) is indicated for: • treatment of mild to moderate essential hypertension in patients for whom combination therapy is appropriate. Patients should be titrated with the individual drugs. If the fixed combination represents the dosage determined by this titration, the use of TARKA may be more convenient in the management of patients. If during maintenance therapy dosage adjustment is necessary, it is advisable to use individual drugs. Both trandolapril and verapamil SR should normally be used in those patients in whom treatment with a diuretic or a beta-blocker were found to be ineffective or were associated with unacceptable adverse effects. They can be tried as initial agents in those patients in whom diuretics and/or beta-blockers are contraindicated or in patients with medical conditions in which these drugs frequently cause serious adverse effects.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02238096 |
|---|---|
| Brand name | TARKA |
| Generic / active ingredient | VERAPAMIL HYDROCHLORIDE : 180 MG TRANDOLAPRIL : 2 MG |
| Manufacturer | ABBOTT LABORATORIES, LIMITED |
| Strength | 180 MG |
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C09BB10 TRANDOLAPRIL AND VERAPAMIL |
| AHFS class | 24:32.04 ; 24:28.92 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 12-Nov-2010 |
| Original market date | 2002-07-15 00:00:00 |
How is it stored and handled?
null
How is it supplied?
null
Is TRANDOLAPRIL AND VERAPAMIL in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by PRO DOC LIMITEE, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code C09BB10 TRANDOLAPRIL AND VERAPAMIL. 0 of 4 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| TARKA | 1 MG | TABLET (EXTENDED-RELEASE) | ABBOTT LABORATORIES, LIMITED | CANCELLED POST MARKET | DIN 02240945 |
| TARKA | 2 MG | TABLET (EXTENDED-RELEASE) | BGP PHARMA ULC | CANCELLED POST MARKET | DIN 02240946 |
| TARKA | 240 MG | TABLET (EXTENDED-RELEASE) | BGP PHARMA ULC | CANCELLED POST MARKET | DIN 02238097 |
Who else supplies TRANDOLAPRIL AND VERAPAMIL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TRANDOLAPRIL AND VERAPAMIL appears in 156 registered pack listings across 6 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.